#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15168	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2116	711.8	0	.	n	.	0	C207T	SNP	207	207	C	459	459	T	799	T,C	585,162	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15168	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2116	711.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1436	1436	C	931	C	880	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28024	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3607	774.8	0	.	n	.	0	T695C	SNP	695	695	T	1072	1072	C	920	C,T	877,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28024	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3607	774.8	0	.	n	.	0	A1638G	SNP	1638	1638	A	2015	2015	G	914	G,A	862,5	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28024	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3607	774.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2348	2348	C	867	C	826	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28024	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3607	774.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2422	2422	A	825	A,G	786,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28024	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3607	774.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2974	2974	C	859	C	814	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1938	folP	855	855	100.0	folP.l6.c30.ctg.1	1562	123.7	1	SNP	p	R229S	1	.	.	685	687	AGC	992	994	AGC	200;200;196	A;G;C	189;189;188	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5030	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3490	143.9	1	SNP	p	S91F	1	.	.	271	273	TTC	656	658	TTC	163;163;166	T;T;C	152;153;154	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5030	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3490	143.9	1	SNP	p	G95N	0	.	.	283	285	GGC	668	670	GGC	160;157;158	G;G;C	149;146;148	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5030	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3490	143.9	1	SNP	p	D95G	1	.	.	283	285	GGC	668	670	GGC	160;157;158	G;G;C	149;146;148	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1562	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1241	124.9	1	SNP	p	G45D	0	.	.	133	135	GGC	392	394	GGC	190;191;193	G;G;C	177;177;179	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	784	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	998	78.3	0	.	n	.	0	A197.	DEL	197	197	A	600	600	A	195	A	185	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2911	198.8	1	SNP	p	D86N	0	.	.	256	258	GAC	608	610	GAC	241;241;239	G;A;C	226;224;227	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2911	198.8	1	SNP	p	R87W	0	.	.	259	261	CGT	611	613	CGT	242;240;237	C,G,A;G;T	228,1,1;224;222	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2911	198.8	1	SNP	p	R87I	0	.	.	259	261	CGT	611	613	CGT	242;240;237	C,G,A;G;T	228,1,1;224;222	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2911	198.8	1	SNP	p	S87R	1	.	.	259	261	CGT	611	613	CGT	242;240;237	C,G,A;G;T	228,1,1;224;222	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2911	198.8	1	SNP	p	S88P	0	.	.	262	264	TCC	614	616	TCC	234;238;238	T;C,G;C	222;223,1;225	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4110	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2642	154.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1526	1528	GGC	201;202;202	G;G;C	185;183;181	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	A311V	0	.	.	931	933	GCC	1147	1149	GCC	217;217;215	G;C;C	205;206;204	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	I312M	1	.	.	934	936	ATG	1150	1152	ATG	216;218;219	A,G;T;G	204,1;208;208	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	V316T	1	.	.	946	948	ACC	1162	1164	ACC	219;219;217	A;C;C	203;205;205	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	T316P	0	.	.	946	948	ACC	1162	1164	ACC	219;219;217	A;C;C	203;205;205	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1663	1665	ACC	209;210;211	A;C;C	187;194;199	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1717	1719	GCG	207;207;210	G;C;G	195;196;199	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1717	1719	GCG	207;207;210	G;C;G	195;196;199	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1840	1842	GGT	179;179;178	G;G;T,C	166;165;164,1	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1849	1851	AGC	169;169;170	A,G;G;C,A	155,1;156;153,1	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3876	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2264	169.7	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1867	1869	CCG	162;166;162	C,G;C,T;G	132,5;134,1;130	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6162	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3016	203.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1516	1518	CCG	218;217;213	C;C;G,C	195;199;189,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2358	porA	1146	1146	99.91	porA.l6.c4.ctg.1	1735	134.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	532	532	C	166	C	154	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3044	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1645	184.2	0	.	p	.	0	I45L	NONSYN	133	135	ATT	453	455	CTT	204;204;209	C,A;T,A;T	195,1;193,1;200	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3044	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1645	184.2	0	.	p	.	0	G210R	NONSYN	628	630	GGA	948	950	AGA	318;314;313	A;G;A	298;293;293	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3044	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1645	184.2	1	SNP	p	G120K	1	.	.	358	360	AAG	678	680	AAG	259;259;264	A;A;G	249;246;245	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3044	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1645	184.2	1	SNP	p	A121N	1	.	.	361	363	AAC	681	683	AAC	264;261;260	A;A;C	251;249;248	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3044	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1645	184.2	1	SNP	p	N121D	0	.	.	361	363	AAC	681	683	AAC	264;261;260	A;A;C	251;249;248	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11584	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4931	234.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1264	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1015	123.6	1	SNP	p	V57M	1	.	.	169	171	ATG	494	496	ATG	256;262;260	A;T;G	245;249;247	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
